Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Graefe s Archive for Clinical and Experimental OphthalmologyOpen Access

Efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration – 6 month results after completion of the loading phase

View Full Paper
Ask AI
Bookmark
Share

Authors

FEFranziska EckardtMHMichael HafnerALAnna Lorger

Discussion

Loading...

Member takes

Overview

Switching to faricimab improves central subfield thickness and injection interval in recalcitrant nAMD, indicating better durability.

Key Points

  • Faricimab reduces central subfield thickness significantly after six months, showing a median drop.
  • Nine months post-switching, 91.1% of patients remained on faricimab, maintaining visual acuity.
  • Patients experienced an increased average injection interval from 37 days to over 56 days after treatment switch.
  • Efficacy of faricimab over older agents like ranibizumab suggests potential for improved management of nAMD.

Cite This Study

Eckardt et al. (2025) studied this question.

synapsesocial.com/papers/68c1a26954b1d3bfb60dd8d4https://doi.org/10.1007/s00417-025-06903-9
View Full Paper
Ask AI
Bookmark
Share